DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.
DNA immunization of macaques with the SF162DeltaV2 envelope elicited lymphoproliferative responses and potent neutralizing antibodies. The animals were depleted of their CD8(+) T lymphocytes and then challenged intravenously with SHIV162P4. Compared to unvaccinated animals, the vaccinated macaques had lower peak viremia levels, rapidly cleared plasma virus, and showed delayed seroconversion.
Cherpelis
S
S
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10021-6399, USA.
Shrivastava
I
I
Gettie
A
A
Jin
X
X
Ho
D D
DD
Barnett
S W
SW
Stamatatos
L
L
D016915:AIDS Vaccines / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000502:physiology*; D015483:HIV Antibodies / Q000097:blood; D015497:HIV-1 / Q000276:immunology*; D008212:Lymphocyte Depletion; D008253:Macaca mulatta; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*
D016915:AIDS Vaccines; D015483:HIV Antibodies; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins